Graig Suvannavejh
Stock Analyst at Mizuho
(4.47)
# 302
Out of 5,239 analysts
171
Total ratings
53.28%
Success rate
20.52%
Average return
Main Sectors:
Stocks Rated by Graig Suvannavejh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IDYA IDEAYA Biosciences | Maintains: Outperform | $52 → $50 | $28.12 | +77.81% | 4 | May 7, 2026 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $228 → $310 | $224.03 | +38.37% | 23 | May 5, 2026 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Outperform | $19 → $21 | $14.44 | +45.43% | 8 | Apr 28, 2026 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $20 → $41 | $41.06 | -0.15% | 13 | Apr 2, 2026 | |
| IMMX Immix Biopharma | Maintains: Outperform | $14 → $15 | $10.66 | +40.71% | 2 | Mar 30, 2026 | |
| INSM Insmed | Maintains: Outperform | $204 → $206 | $116.00 | +77.59% | 14 | Mar 25, 2026 | |
| PVLA Palvella Therapeutics | Maintains: Outperform | $205 → $250 | $125.79 | +98.74% | 2 | Feb 25, 2026 | |
| LONA LeonaBio | Upgrades: Outperform | $10 | $10.17 | -1.67% | 1 | Feb 19, 2026 | |
| ERAS Erasca | Maintains: Outperform | $4 → $5 | $10.38 | -51.83% | 1 | Dec 9, 2025 | |
| BLTE Belite Bio | Upgrades: Outperform | $105 → $194 | $155.54 | +24.73% | 2 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $39 → $46 | $30.15 | +52.57% | 21 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $100 | $59.83 | +67.14% | 1 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $23 | $11.39 | +101.93% | 4 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $54 → $56 | $70.93 | -21.05% | 7 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $2 → $4 | $1.19 | +236.13% | 9 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $3.12 | +861.54% | 1 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2.5 → $3.5 | $2.16 | +62.04% | 5 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $5 | $1.90 | +163.16% | 2 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $10 | $5.18 | +93.05% | 2 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $11 | $15.97 | -31.12% | 3 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $26 | $13.62 | +90.90% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $33 | $29.30 | +12.63% | 8 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 → $7.6 | $1.60 | +375.00% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $11.43 | +547.42% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $1 | $1.45 | -31.03% | 5 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $35 | $91.31 | -61.67% | 5 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $39.49 | -79.74% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $57 | $74.81 | -23.81% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $5 | $42.54 | -88.25% | 4 | Apr 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $6.00 | +466.67% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $15.79 | +77.33% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $31 | $34.01 | -8.85% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $380 | $16.47 | +2,207.23% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $4.75 | $1.36 | +249.26% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $20.69 | +74.00% | 2 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $37 | $4.64 | +697.41% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $128 | $227.84 | -43.82% | 1 | Sep 14, 2020 |
IDEAYA Biosciences
May 7, 2026
Maintains: Outperform
Price Target: $52 → $50
Current: $28.12
Upside: +77.81%
Axsome Therapeutics
May 5, 2026
Maintains: Outperform
Price Target: $228 → $310
Current: $224.03
Upside: +38.37%
Amylyx Pharmaceuticals
Apr 28, 2026
Maintains: Outperform
Price Target: $19 → $21
Current: $14.44
Upside: +45.43%
Apellis Pharmaceuticals
Apr 2, 2026
Maintains: Neutral
Price Target: $20 → $41
Current: $41.06
Upside: -0.15%
Immix Biopharma
Mar 30, 2026
Maintains: Outperform
Price Target: $14 → $15
Current: $10.66
Upside: +40.71%
Insmed
Mar 25, 2026
Maintains: Outperform
Price Target: $204 → $206
Current: $116.00
Upside: +77.59%
Palvella Therapeutics
Feb 25, 2026
Maintains: Outperform
Price Target: $205 → $250
Current: $125.79
Upside: +98.74%
LeonaBio
Feb 19, 2026
Upgrades: Outperform
Price Target: $10
Current: $10.17
Upside: -1.67%
Erasca
Dec 9, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $10.38
Upside: -51.83%
Belite Bio
Dec 2, 2025
Upgrades: Outperform
Price Target: $105 → $194
Current: $155.54
Upside: +24.73%
Dec 1, 2025
Maintains: Outperform
Price Target: $39 → $46
Current: $30.15
Upside: +52.57%
Nov 20, 2025
Initiates: Outperform
Price Target: $100
Current: $59.83
Upside: +67.14%
Nov 19, 2025
Maintains: Outperform
Price Target: $19 → $23
Current: $11.39
Upside: +101.93%
Nov 18, 2025
Maintains: Neutral
Price Target: $54 → $56
Current: $70.93
Upside: -21.05%
Sep 12, 2025
Maintains: Neutral
Price Target: $2 → $4
Current: $1.19
Upside: +236.13%
Sep 8, 2025
Initiates: Outperform
Price Target: $30
Current: $3.12
Upside: +861.54%
Jul 28, 2025
Upgrades: Outperform
Price Target: $2.5 → $3.5
Current: $2.16
Upside: +62.04%
Jul 16, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $1.90
Upside: +163.16%
Jun 18, 2025
Maintains: Outperform
Price Target: $8 → $10
Current: $5.18
Upside: +93.05%
May 20, 2025
Maintains: Outperform
Price Target: $12 → $11
Current: $15.97
Upside: -31.12%
May 16, 2025
Maintains: Outperform
Price Target: $30 → $26
Current: $13.62
Upside: +90.90%
Apr 7, 2025
Maintains: Neutral
Price Target: $38 → $33
Current: $29.30
Upside: +12.63%
Nov 18, 2024
Upgrades: Buy
Price Target: $7 → $7.6
Current: $1.60
Upside: +375.00%
Sep 20, 2024
Reiterates: Outperform
Price Target: $74
Current: $11.43
Upside: +547.42%
Jun 5, 2023
Downgrades: Neutral
Price Target: $17 → $1
Current: $1.45
Upside: -31.03%
Nov 10, 2022
Maintains: Buy
Price Target: $31 → $35
Current: $91.31
Upside: -61.67%
Nov 10, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $39.49
Upside: -79.74%
May 24, 2022
Maintains: Buy
Price Target: $71 → $57
Current: $74.81
Upside: -23.81%
Apr 19, 2022
Maintains: Sell
Price Target: $8 → $5
Current: $42.54
Upside: -88.25%
Jun 1, 2021
Initiates: Buy
Price Target: $34
Current: $6.00
Upside: +466.67%
Apr 20, 2021
Initiates: Neutral
Price Target: $28
Current: $15.79
Upside: +77.33%
Apr 19, 2021
Initiates: Neutral
Price Target: $31
Current: $34.01
Upside: -8.85%
Mar 2, 2021
Initiates: Sell
Price Target: $380
Current: $16.47
Upside: +2,207.23%
Nov 24, 2020
Initiates: Neutral
Price Target: $4.75
Current: $1.36
Upside: +249.26%
Nov 9, 2020
Upgrades: Buy
Price Target: $36
Current: $20.69
Upside: +74.00%
Oct 20, 2020
Initiates: Neutral
Price Target: $37
Current: $4.64
Upside: +697.41%
Sep 14, 2020
Downgrades: Sell
Price Target: $128
Current: $227.84
Upside: -43.82%